at CNBC.com (Dec 17, 2014)
A U.S. appeals court upholds a lower court ruling in favor of Pozen (POZN -0.8%) against Par...
A U.S. appeals court upholds a lower court ruling in favor of Pozen (POZN -0.8%) against Par Pharmaceutical (PRX), Alphapharm and Dr. Reddy’s Laboratories (RDY +1.9%), affirming the district court's earlier decision that found POZN's patent valid, and blocked PRX and RDY from selling a generic version of POZN's migraine drug Treximet until 2025.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs